LYZZ Capital is a global healthcare-dedicated VC/PE firm actively investing out of USD and RMB funds totaling over USD$600 million. The firm focuses on identifying and investing in talents, assets, and technologies globally, with a particular emphasis on addressing unmet medical needs and targeting opportunities with large market potential in China. Their investment approach is rooted in a deep understanding of the pharmaceutical and biotech industries, leveraging the extensive experience of their team members who come from leading pharmaceutical/biotech companies and Wall Street firms. LYZZ Capital's investment strategy is characterized by a long-term perspective, built on over 20 years of biotech investment experience, including more than 15 years of presence in China. They seek to partner with innovative companies and entrepreneurs who are developing groundbreaking solutions to address significant healthcare challenges. The firm's experienced management team fosters a cordial and team-oriented working environment, facilitating collaboration and informed decision-making. With a substantial AUM and a strong network of industry contacts, LYZZ Capital is well-positioned to provide not only financial resources but also strategic guidance and operational support to their portfolio companies. They are committed to helping their portfolio companies navigate the complexities of the global healthcare market and achieve their full potential. Their established presence in both the US and China allows them to facilitate cross-border collaborations and leverage the unique strengths of each market.
Preferred startup development maturity for initial funding deployment.
Healthcare, Pharmaceutical, Biotech, Medical Technologies
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...